Open Access

[Retracted] Epigenetic silencing of miR‑130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling

  • Authors:
    • Feng Gao
    • Fa-Gang Wang
    • Ren-Rong Liu
    • Feng Xue
    • Jian Zhang
    • Guang-Qi Xu
    • Jian-Hai Bi
    • Zhen Meng
    • Ran Huo
  • View Affiliations

  • Published online on: October 20, 2020     https://doi.org/10.3892/ijo.2020.5136
  • Pages: 1383-1383
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Int J Oncol 50: [Related article:] 1821-1831, 2017; DOI: 10.3892/ijo.2017.3943

Following the publication of this paper, it was drawn to the authors' attention by an interested reader that some tumours featured in Fig. 6A of the above paper were strikingly similar to those featured in Fig. 8A of an article appearing in the same journal [Fan F-Y, Deng R, Yi H, Sun H-P, Zeng Y, He G-C and Su Y: The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma. Int J Oncol 51: 316-326, 2017]. Furthermore, flow cytometric images featured in Fig. 2G of the above paper were strikingly similar to data featured in the following article [Zhang H-j, Wei Q-f, Wang S-j, Zhang H-j, Zhang X-y, Geng Q, Cui Y-h and Wang X-h: LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-κB pathway. Int Immunopharmacol 50: 283-290, 2017].

The Editor asked the authors for an explanation to account for the appearance of strikingly similar data in their paper independently, and they responded to request that the paper be retracted from International Journal of Oncology. All the authors agreed that the article should be retracted. The Editor apologizes to the readership for any inconvenience caused.

Related Articles

Journal Cover

December-2020
Volume 57 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao F, Wang F, Liu R, Xue F, Zhang J, Xu G, Bi J, Meng Z and Huo R: [Retracted] Epigenetic silencing of miR‑130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling. Int J Oncol 57: 1383-1383, 2020
APA
Gao, F., Wang, F., Liu, R., Xue, F., Zhang, J., Xu, G. ... Huo, R. (2020). [Retracted] Epigenetic silencing of miR‑130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling. International Journal of Oncology, 57, 1383-1383. https://doi.org/10.3892/ijo.2020.5136
MLA
Gao, F., Wang, F., Liu, R., Xue, F., Zhang, J., Xu, G., Bi, J., Meng, Z., Huo, R."[Retracted] Epigenetic silencing of miR‑130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling". International Journal of Oncology 57.6 (2020): 1383-1383.
Chicago
Gao, F., Wang, F., Liu, R., Xue, F., Zhang, J., Xu, G., Bi, J., Meng, Z., Huo, R."[Retracted] Epigenetic silencing of miR‑130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling". International Journal of Oncology 57, no. 6 (2020): 1383-1383. https://doi.org/10.3892/ijo.2020.5136